JoshuaFranklinZeidnerMD

PubMed

• Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.
  Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yi-Chun Lin, Song-Bai Liu, Huafeng Wang, Le Xuan Truong Nguyen, Min Li, Yinghui Zhu, Dandan Zhao, Lucy Ghoda, Jonathan Serody...> ;Nature Cancer. 2024 Feb 27
• A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
  Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
• Comprehensive genomic profiling reveals molecular subsets of-mutated myeloid neoplasms.
  Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs, Daniel R Richardson, Matthew C Foster, Daniel Duncan, Nathan D Montgomery,...> ;Leukemia & Lymphoma. 2024 Feb 1
• 2 citations
  Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...
  Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, ...> ;Journal of Clinical Oncology. 2023 Nov 1
• 3 citations
  Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
• 1 citations
  A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.
  Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs, Daniel R Richardson, Matthew C Foster, Daniel Duncan, Joshua F Zeidner, Na...> ;Blood Cancer Journal. 2023 Jun 26
• 1 citations
  Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.
  Joshua F Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J Fram, Douglas V Faller, Mehul Dalal, Lionel Ades, Mikka...> ;Haematologica. 2023 Apr 1
• Outpatient initiation of venetoclax in patients with acute myeloid leukemia.
  Shannon Palmer, Anand Patel, Christopher Wang, Bianka Patel, Joshua Zeidner, Matthew Foster, Benyam Muluneh, Kaitlyn Buhlinger> ;Journal of Oncology Pharmacy Practice. 2023 Oct 1
• Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.
  Christopher E Jensen, Nathan D Montgomery, Jonathan Galeotti, Matthew C Foster, Joshua F Zeidner> ;Journal of Cellular and Molecular Medicine. 2022 Dec 1
• 19 citations
  Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
  Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung-On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Kramer, Hann...> ;The Journal of Clinical Investigation. 2022 Nov 1
• TP53 or Not TP53: That Is the Question.
  Steven D Green, Joshua F Zeidner> ;Clinical Cancer Research. 2022 Dec 15
• 2 citations
  Association of QTc Formula With the Clinical Management of Patients With Cancer.
  Daniel R Richardson, P Christopher Parish, Xianming Tan, Julia Fabricio, Cami L Andreini, Charles H Hicks, Brian C Jensen, Benyam Muluneh, Joshua F Zeidner> ;JAMA Oncology. 2022 Nov 1
• Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains.
  Justin D Woods, Joshua F Zeidner, Hendrik W Van Deventer, Katarzyna Jamieson, Melissa Matson, Jack Zhang, William Pulley, Tucker Brenizer, Hyman Muss, Kirsten A Nyrop,...> ;Journal of Geriatric Oncology. 2022 May 1
• 3 citations
  The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
  Anson Snow, Joshua F Zeidner> ;Therapeutic Advances in Hematology. 2022 Jan 1
• 2 citations
  Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
  Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Patricia Font Lopez, Joshua F. Zeidner, Maria Diez Campelo, Carlos Gra...> ;Leukemia. 2021 Nov 17
• 3 citations
  A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
  Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen W.L. Yee, Andrew Dalovisio, Eunice S. Wang, Jua...> ;Blood Cancer Journal. 2021 Oct 30
• Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.
  Nathan D. Montgomery, Jonathan Galeotti, Steven M Johnson, Leah Commander, Eric T. Weimer, Pranil K. Chandra, Tariq Nazir, Thomas B. Alexander, Joshua F. Zeidner, Matt...> ;Blood Advances. 2021 Sep 28
• 1 citations
  Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
  Andy H. Szeto, Tyler Bucci, Allison M. Deal, Anqi Zhu, Majd Ahmad, Amanda S Cass, Margaret R Sketch, Ryan Kemper, Joshua F. Zeidner, Matthew C. Foster, Benyam Muluneh,...> ;The Annals of Pharmacotherapy. 2021 Sep 18
• 37 citations
  Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
  Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec D. Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A....> ;Blood Cancer Discovery. 2021 Sep 10
• 14 citations
  Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia.
  Nicholas Tschernia, Vaibhav Kumar, Dominic T. Moore, Benjamin G. Vincent, Catherine C. Coombs, Hendrik W. van Deventer, Matthew C. Foster, Amy E. DeZern, Leo Luznik, M...> ;Transplantation and Cellular Therapy. 2021 Aug 30
• Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle.
  Davis F Phillips, Joshua F. Zeidner> ;Expert Opinion on Emerging Drugs. 2021 Jul 6
• Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
  Lori A Ramkissoon, Kaitlyn Buhlinger, Angela Nichols, Catherine C Coombs, Matthew C Foster, Jonathan Galeotti, Kathleen Kaiser-Rogers, Daniel R Richardson, Nathan D Mo...> ;Leukemia & Lymphoma. 2021 Dec 1
• 6 citations
  CD123-targeted therapy in acute myeloid leukemia.
  Manuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F. Zeidner, Heiko Konig> ;Expert Review of Hematology. 2021 May 27
• 6 citations
  Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
  Daniel R. Richardson, Steven D. Green, Matthew C. Foster, Joshua F. Zeidner> ;Current Hematologic Malignancy Reports. 2021 Feb 1
• 13 citations
  Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia
  Daniel R. Richardson, David M Swoboda, Dominic T. Moore, Steven M Johnson, Onyee Chan, Jonathan Galeotti, Sonia Esparza, Mohammad Hussaini, Hendrick W. van Deventer, M...> ;American Journal of Hematology. 2021 Apr 1
• Join now to see all

Journal Articles

• Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...  
  Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research

Abstracts/Posters

• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)
  Joshua Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Joshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors
  Joshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Joshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018